|
Program
8.45 - 9.00
Introduction & Welcome
H. Reichmann, Dresden, Germany
Session I
Chair: H. Reichmann
09.00–09.25
Parkinson’s Disease Pathoanatomy—How Early Does the Multisystem Disorder Begin?
H. Braak, Frankfurt, Germany
09.25–09.50
Neuroprotection Remains an Elusive Treatment Goal—Update on Most Recent Clinical Trials
A. Schapira, London, UK
09.50–10.05
Panel Discussion / Q&A
10.05–10.20
Coffee Break
Session II
Chair: Heinz Reichmann
10.20–10.45
The Concept of Continuous Dopaminergic Delivery: Relevance to Prolonged-Release Dopamine Agonists
P. Jenner, London UK
10.45–11.10
Clinical Aspects of Once-Daily Pramipexole
W. Poewe, Innsbruck, Austria
11.10–11.35
Clinical Advantages of Continuous Drug Delivery
Y. Mizuno, Tokyo, Japan
11.35–12.00
Panel Discussion / Q&A
12.00–13.30
Lunch Break
Session III
Chair: Anthony Schapira
13.30–13.50
Predictors of Quality of Life in Parkinson’s Disease Patients
P. Barone, Naples, Italy
13.50–14.10
Depressive Symptoms in Parkinson’s Disease—State-of-the-Art Treatment
H. Reichmann, Dresden, Germany
14.10–14.30
Medication Adherence in Parkinson’s Disease Patients
E. Tolosa, Barcelona, Spain
14.30–14.45
Panel Discussion / Q&A
14.45–15.00
Coffee Break
Session IV
Chair: Anthony Schapira
15.00–16.30
Video Session: Management Challenges in Movement Disorders
A. Albanese, E. Melamed, W. Oertel, K. Sethi
16.30–17.00
Keynote Lecture: Compliance—A Public-Health Issue
F.-U. Fricke, Nuremberg, Germany
17.00–17.20
Discussion
17.20 –17.30
Summary and Close
A. Schapira
|
|
|
